Role of FABP5 in COPD Flare-Ups
Official title: Role of FABP5 in COPD Exacerbations
Funded at National Jewish Health · NIH-11364163 · Data updated 2026-11-12
Aims to understand how a protein called FABP5 helps lung immune cells control inflammation during COPD flare-ups and whether this could lead to new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Jewish Health NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | June 15, 2019 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $574,768 |
| NIH project number | 5R01HL141264-07 |
| Project ID | NIH-11364163 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with COPD or related airway inflammatory conditions who may provide samples or participate in related studies.
✕Less likely to help
People without COPD or those not contributing samples or participating in related sub-studies may not benefit.
What this research studies
This project looks at how fatty acid binding protein 5 (FABP5) influences lung macrophages during COPD exacerbations. Researchers will study how FABP5 interacts with PPARγ to push macrophages toward a repair-friendly state and how a COPD-linked genetic variant might affect this process. By examining patient-derived samples and experimental models, the team hopes to identify targets that could reduce inflammation and prevent worsened symptoms. The goal is to uncover mechanisms that could be turned into therapies to improve lung health for people with COPD.
Why it matters
Potential benefit: If successful, the research could lead to new ways to prevent COPD flare-ups and improve breathing by targeting FABP5-related pathways.
How similar studies have gone: Previous work suggests FABP5 and the FABP5/PPARγ axis influence macrophage behavior; this study tests their therapeutic potential in COPD.
Where this research is happening
-
National Jewish Health
Denver, United States Active
Researchers
- Principal investigator: Gally, Fabienne — National Jewish Health
- Study coordinator: Gally, Fabienne
Related research
Other NIH-funded projects on the same topics.
-
Omalizumab for COPD patients with allergen sensitization and exposure
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Next-Generation Wearable AI for Precision COPD Risk and Care
A patient-centered project uses a smart wearable and AI to predict COPD flare-ups and support doctors in making better care decisions.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
Easier, local pulmonary rehab and social support for people with COPD in low-resource clinics
This project compares a 10-week community pulmonary rehabilitation program alone, the same program plus help with social needs, and usual care for people with moderate-to-severe COPD to see which helps people stick with rehab and feel better.
-
Improving COPD outcomes with real-world data
A doctor-scientist at a major university is using real-world information from COPD patients to understand which treatments work best, how safe they are, and whether people stick to their inhaler plans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.